Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Stopped Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative therapy and clinician's choice to put patient on immunotherapy outside of trial setting.

Conditions

• Non-Small Cell Lung Cancer

Interventions

• DRUG: Ipilimumab
• DRUG: Nivolumab

Sponsor

National Cancer Centre, Singapore

Collaborators

• [object Object]
• [object Object]